SCHEMBL13828448

SCHEMBL13828448

Cc1cccc2oc([C@@H](C)OCc3ccccc3)c(-c3ccccc3)c(=O)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 1/20 0.39
▸ MCL1 Q07820 1/20 0.39
▸ EDNRA P25101 1/20 0.37
▸ PPARG P37231 2/20 0.36
▸ CDK1 P06493 1/20 0.35
▸ CCNB1 P14635 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ CDK5 Q00535 1/20 0.35
▸ CDK5R1 Q15078 1/20 0.35
▸ MAOB P27338 3/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ PKM P14618 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ MAOA P21397 1/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SENP8 Q96LD8 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34
▸ SENP6 Q9GZR1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13718641 1.00 BCL2 (0.39) BCL2MCL1EDNRAPPARGCDK1
SCHEMBL13828423 1.00 BCL2 (0.39) BCL2MCL1EDNRAPPARGCDK1
SCHEMBL20088117 0.89 HPGD (0.37) BCL2MCL1EDNRAMAOBL3MBTL1
SCHEMBL21365159 0.87 AR (0.41) BCL2MCL1EDNRAPPARGMAOB
SCHEMBL13825908 0.85 BCL2 (0.35) BCL2MCL1ALDH1A1CYP3A4MAPT
SCHEMBL13826004 0.85 BCL2 (0.35) BCL2MCL1ALDH1A1CYP3A4MAPT
SCHEMBL16584880 0.84 CA1 (0.50) PKMMAOAALDH1A1KDM4EMEN1
SCHEMBL15528063 0.84 CA1 (0.50) PKMMAOAALDH1A1KDM4EMEN1
SCHEMBL13826314 0.81 KDM4E (0.41) BCL2MCL1L3MBTL1PKMTDP1
SCHEMBL13825904 0.81 KDM4E (0.41) BCL2MCL1L3MBTL1PKMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11478481-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals RHIZEN PHARMACEUTICALS AG (CH) 2022-10-25 — — US disclosed
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2021-12-30 — — US disclosed
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2021-06-01 — — US disclosed
EP-2844647-B1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS S A (CH) 2020-07-22 — — EP disclosed
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-09-19 — — US disclosed
US-10322130-B2 Substituted chromenones as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-06-18 — — US disclosed
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-04-11 — — US disclosed
US-10220035-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-03-05 — — US disclosed
US-20190038634-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS AG (CH) 2019-02-07 — — US disclosed
US-10130635-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals RHIZEN PHARMACEUTICALS SA (CH) 2018-11-20 — — US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 — — US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 — — US disclosed
US-20180098994-A9 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS AG (CH) 2018-04-12 — — US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 — — US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 — — US disclosed
US-20170266196-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS SA (CH) 2017-09-21 — — US disclosed
US-9309216-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals RHIZEN PHARMACEUTICALS SA (CH) 2016-04-12 — — US disclosed
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2015-11-12 — — US disclosed
US-20150087699-A1 NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS AG (CH) 2015-03-26 — — US disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB BCL2 1059/4885MCL1 767/4885EDNRA 1619/4885
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases MAP4K2, MAP3K20, MAP3K1 BCL2 1499/4885MCL1 503/4885EDNRA 1974/4885
US-20190038634-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS CYP4B1, ADH1A, CYP1A2 BCL2 4846/4885MCL1 4636/4885EDNRA 2441/4885
US-20150087699-A1 NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS CYP4B1, ADH1A, CYP1A2 BCL2 4868/4885MCL1 4696/4885EDNRA 2404/4885
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB BCL2 1059/4885MCL1 767/4885EDNRA 1619/4885
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB BCL2 1059/4885MCL1 767/4885EDNRA 1619/4885
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKAR2B BCL2 1161/4885MCL1 1177/4885EDNRA 1155/4885
US-11478481-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals CYP4B1, ADH1A, CYP1A2 BCL2 4846/4885MCL1 4636/4885EDNRA 2441/4885
US-10220035-B2 Compounds as modulators of protein kinases PRKCA, PRKCH, PRKCE BCL2 866/4885MCL1 699/4885EDNRA 1727/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB BCL2 1059/4885MCL1 767/4885EDNRA 1619/4885
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB BCL2 1059/4885MCL1 767/4885EDNRA 1619/4885
US-20180098994-A9 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS CYP4B1, ADH1A, CYP1A2 BCL2 4846/4885MCL1 4636/4885EDNRA 2441/4885
US-10322130-B2 Substituted chromenones as modulators of protein kinases MAP3K1, CSNK1A1, MAP3K2 BCL2 699/4885MCL1 1260/4885EDNRA 1685/4885
US-20170266196-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS CYP4B1, ADH1A, CYP1A2 BCL2 4846/4885MCL1 4636/4885EDNRA 2441/4885
US-10130635-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals CYP4B1, ADH1A, CYP1A2 BCL2 4846/4885MCL1 4636/4885EDNRA 2441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback